Time toxicity during palliative chemotherapy for advanced malignancies: a prospective study Authors: Sharada Mailankody, Divyashree Kotian, Karthik S Udupa, Ananth Pai, Prajna Shetty, Vasudeva Guddattu, Prasanth Ganesan Published: 2025 ABSTRACT AbstractObjectivesPatients with advanced malignancies spend a considerable proportion of their limited survival time on healthcare. However, it is not usual practice to consider ‘time spent for therapy’ when making treatment decisions. This study aimed to calculate the time toxicity associated with systemic therapy in advanced malignancies.MethodsThe study was a prospective (CTRI/2023/05/053281) single-centre study that included adult patients with advanced malignancies receiving palliative intravenous systemic therapy. The time spent away from home for the hospital visit was considered time toxicity. Time toxicity over the 2-month period, divided by total follow-up duration, was calculated to derive the time toxicity index. The time taken for the different activities determined the components of time toxicity. Time toxicity was correlated with patient quality of life.ResultsOf the 92 recruited patients, the median age was 57 (35–88) years, 39 (42%) were women and 34 (37%) patients had gastrointestinal cancers. The median survival time was 7.6 (95% CI 5.6 to not reached) months. The mean time toxicity over the study period was 226 hours (95% CI 194 to 258.7) and time toxicity index was 17% (95% CI 14% to 20.5%). The major components of time toxicity were travel time and hospital formalities. Mean proportion of necessary to non-value-added activities was 8 (SD 9.4). The time toxicity index correlated with QoL.ConclusionsThe study highlights that time toxicity is an important factor in decision-making for patients planned for palliative therapy. Further studies are needed to understand the impact of time toxicity and the meaning patients attach to this.Trial registration numberCTRI/2023/05/053281.Keywords: Advance Care Planning, Clinical decisions, End of life care, Medical Oncology, Service evaluation, Supportive care WHAT IS ALREADY KNOWN ON THIS TOPIC Patients with advanced cancer may spend a considerable proportion of their survival time on healthcare related activities, described as ‘time toxicity’. Patients with advanced cancer may spend a considerable proportion of their survival time on healthcare related activities, described as ‘time toxicity’. WHAT THIS STUDY ADDS This prospective study reports the mean time toxicity and the predominant components of time toxicity, such as travelling or waiting times. The study revealed that patients with advanced malignancies spend nearly one-fifth of their time in the hospital for healthcare-related activities, a large proportion of which may be waiting or travelling. This prospective study reports the mean time toxicity and the predominant components of time toxicity, such as travelling or waiting times. The study revealed that patients with advanced malignancies spend nearly one-fifth of their time in the hospital for healthcare-related activities, a large proportion of which may be waiting or travelling. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY The study serves to provide baseline information for all stakeholders to optimise care for patients with advanced malignancies. The study serves to provide baseline information for all stakeholders to optimise care for patients with advanced malignancies. The information from the study will help in providing goal-concordant care to patients with advanced cancers. The information from the study will help in providing goal-concordant care to patients with advanced cancers. However, further studies are required to study the impact of time toxicity on patients and caregivers. However, further studies are required to study the impact of time toxicity on patients and caregivers. Introduction Palliative systemic therapy for advanced cancer is a nuanced decision that needs to balance several risks and benefits. Generally, oncologists and patients discuss and consider several factors such as disease biology, likely response to treatment, toxicities of treatment and even the cost of therapy. The ultimate aim is to achieve ‘goal-concordant’ care of the patient, the so-called ‘holy grail’ of palliative care.1 However, patients and oncologists may not be consciously aware of the recently emerged concept of time toxicity (online supplemental Figure 1). The term ‘time toxicity’ was coined to account for the time spent by patients seeking healthcare.2 Patients may spend time on multiple processes involved in healthcare, such as travel to the hospital, appointments with doctors, emergency room visits for supportive care, laboratory investigations, waiting for reports/doctor appointments, insurance formalities and admission to the hospital for intravenous infusion therapies, to name a few.2,4 Many hospital visits, such as admissions for febrile neutropenia, chemotherapy administration visits and response assessment scans, may be necessary and unavoidable. For patients with metastatic malignancies with limited survival, the time spent in the hospital may prevent them from performing meaningful, pleasurable activities.5 6 Patients need to obtain the right information to understand the goals of care and participate in the ‘shared decision-making’ process.7 8 There are prior retrospective studies from other countries suggesting that patients may spend even one-third of their survival time on healthcare-related activities.6 9 10 Even cancer survivors may require around 30 days of healthcare contact per year, although predominantly for ambulatory care.11 However, the time burdens of care may become more significant in the scenario of limited survival times, as the treatment may limit the activities of the patient in the short survival time.12 India is a low-income and middle-income country (LMIC) where the overall cancer burden has been increasing.13 The cancer distribution, cancer care models and access to cancer care and patient priorities are distinct in India. The increasing incidence of cancer and more advanced stages at presentation contribute to an increased number of patients receiving palliative chemotherapy.14 15 Patients with cancer may have to travel long distances for treatment purposes.16,18 There may also be considerable financial toxicity associated with treatment due to increased out-of-pocket expenditures.19 20 The caregivers accompanying the patient may also lose their income and suffer during treatment. Patients’ priorities and treatment goals may also differ in India, as demonstrated by the different published perspectives on cancer treatment and communication preferences.21,25 The Indian scenario of palliative therapy and the time costs associated with the therapy are unexplored. Although time toxicity is a recently described entity, researchers have studied multiple aspects of time toxicity in patients receiving palliative therapy in high-income countries.5 6There are no prior studies in India looking at the time spent by patients seeking palliative systemic therapy. The current study is a prospective study to quantify the time toxicity associated with palliative treatment from a single tertiary cancer centre in India. This study also investigated the factors associated with time toxicity. The knowledge generated will help oncologists factor in time toxicity while counselling patients with advanced cancers and designing studies to further understand the determinants and perspectives of time toxicity in India. Methodology We conducted a single-centre prospective observational study (CTRI/2023/05/053281) to determine the time toxicity in patients receiving palliative intravenous systemic therapy. All adult patients with advanced malignancies undergoing systemic intravenous palliative intent therapy from the medical oncology department of Kasturba Medical College, Manipal, Karnataka, India, from January 2024 to July 2024 were included in the study within 2 months of the start of the current line of systemic therapy. Patients who decided on best supportive care only were excluded from the study. Patients who planned only for oral chemotherapy were also excluded from the study, as the concerns associated with oral chemotherapy are distinct. Since this was an observational study and there was no prior Indian data, convenient sampling was used to recruit patients during the study period. The study schema and procedures are described in figure 1. Baseline demographic profile (age, gender, educational qualification and occupation), disease and treatment details were collected at patient enrolment. For the present study, the time toxicity was calculated as the number of hours spent away from home during the 2-month follow-up. The time toxicity index was calculated via the following formula: time spent (in hours) away from home/total duration of follow-up (in hours). Prior studies have used varying definitions to quantify time toxicity. Any day with contact with the healthcare system was considered time toxicity in most of the studies.5 11 26 27 Since this is the first study on time toxicity from India using a prospective methodology, we used a more comprehensive but similar definition of time away from home for the hospital visit, with a detailed description of the individual components of the time toxicity. Study schema. The time taken for each hospital visit (from when the patient leaves home until the patient reaches home) was computed from patient interviews at each hospital visit. To calculate the total hours spent for a specific hospital visit, the study investigators ascertained when the patient reached home telephonically, on the same day. Any unscheduled hospital visits for blood investigations and supportive care were also included in the time toxicity calculation; the details of hospital movements were not collected in such cases. At each visit, patients were additionally questioned by the study team regarding visits to local laboratories or other unscheduled hospital visits or care with primary care physicians. Additionally, the patients were asked to relate the details of the time spent at each hospital section to clarify the components of time toxicity, based on oral recall. The routine expected movements of a patient arriving at the hospital to receive systemic therapy or supportive care in the medical oncology department are shown in figure 2. The department routinely admits patients for the first chemotherapy cycle. After the first cycle, further admissions are indicated for insurance purposes, infusional therapies or patient requests. Additionally, after the first chemotherapy cycle, patients are asked to review with the oncology team with a complete blood count to assess the toxicity during the expected nadir count period. The expected patient movements during a typical hospital visit demonstrating the different components of time toxicity. The different prespecified components of time toxicity (figure 2) based on the expected patient movements were travel time (C1) which included onward journeys—from the time they leave home until they reach the hospital and return home from the hospital), waiting for file entry and registration, laboratory blood tests and venesection (inclusive of all steps) (C2), doctor waiting time (C3), the turnaround time for laboratory plus consultant consult (C4), time for billing the chemotherapy (C5), pharmacy (C6), infusion (C7) which includes both the time taken for infusion and the time taken to wait for the daycare slot, time for meal (C8). The time components were summarised into the following categories: travel time (C1), hospital formalities and waiting times (C2+C3+C5+C6), infusion time (C7) and doctor consultation time (C4). Furthermore, the infusion and doctor consultation times (C7 and C4) were considered necessary, and the rest were deemed non-value-added activities. The ratio of necessary to non-value-added activities was also calculated. The total time toxicity was calculated only from the total time spent away from home, whereas the components were based on the oral recall of the patients. In the case of admitted patients, the total length of hospital stay and travel duration was included to calculate time toxicity. The authors also noted the purpose of the hospital visits, the reason for admission and the disease status. The data was collected for 2 months after study enrolment. The sum of the individual visit time durations (in hours) was used to compute the time toxicity index. The team also telephonically contacted any patient who did not visit for an appointment during the 2 months to assess the patient’s status. After the 2-month study period, patient survival status was ascertained telephonically to calculate survival times, until the study follow-up period of a minimum of 6 months after enrolment. The overall survival time was calculated from the date of study enrolment to the date of death or last follow-up. The data were censored on 10 January 2025. The data of patients with less than 14 days of follow-up were not included for the time toxicity calculation. The quality of life (QoL) was also evaluated at baseline and at the end of the follow-up period. The EuroQoL-5D-3L (five-dimensional, three-level) was used for QoL estimation in this study. The EuroQoL Questionnaire was administered by proxy/telephonically in situations where the patient could not provide the details.28 Statistical analysis The data were entered into MS Excel and imported into Jamovi V.2.6.13 software for analysis. Descriptive statistics were reported for the baseline characteristics of the participants. Since the Indian value set was not available for EuroQoL 5D-3L, the QoL values from Thailand were used.29 Baseline characteristics were summarised by frequency and percentage. Normally distributed variables were summarised by mean and SD, while skewed variables were summarised by median and IQR. Since the time toxicity index was skewed, we used log transformation and summarised the log-transformed values by geometric mean and SD. Gamma regression with a log link was used to find factors associated with the time toxicity index. The actuarial survival of the study population was calculated using the Kaplan-Meier method. All percentage values were rounded to the nearest whole number. Results Study participants From February 2024 to July 2024, 109 patients were screened and 92 were included and available for the final analysis (figure 3). Participants had a median age of 57 years (range 35–88), and 39 (42%) were women. Most patients were only primary literates (71, (77%)) (fewer than 10 years of formal schooling). Thirty (37%) patients had gastrointestinal cancers, 18 (20%) lung cancer and 13 (14%) breast cancer. Among the 92 patients, 33 (36%) were homemakers, 18 (20%) were working in -elementary occupations, 28 (30%) had no formal occupation at the time of data collection and 11 (18%) were in other professions, that is, professionals, managers, clerical support workers, craft and related trade workers and technicians. Study flow chart. 57 (62%) patients used private transport (ie, car, autorickshaws and two-wheelers), and 35 (38%) used public transport (ie, bus, train) as the predominant mode of travel. The median distance from the hospital was 60 km (range 5–395). Forty-eight (52%) of the patients were receiving first-line therapy, while others were receiving treatment in second (25 (27%)), third (10 (11%)), fourth (8 (9%)) and fifth (1 (1%)) lines of therapy. For 63 (69%) patients, no further lines of chemotherapy were used, whereas 25 (27%) patients received one more line of therapy after the current line of treatment. The baseline characteristics of the patients are summarised in table 1. The time toxicity index for each subgroup is also summarised. Table 1Baseline characteristics of included patientsCharacteristicsn (%)Geometric mean (SD)P valueAge 18–394 (4)23.6±2.40.192 40–5951 (55)13.6±2.2 >6037 (40)10.7±2.1Gender Male53 (58)13.3±2.20.48 Female39 (42)11.8±2.2Educational status Primary literate71 (77)13.4±2.20.001 Intermediate/diploma8 (9)9.1±2 Graduate and above13 (14)11.3±2.1Type of cancer Gastrointestinal34 (37)11.7±2.30.483 Lung18 (20)11.0±2.3 Breast13 (14)13.05±1.8 Gynaecological11 (12)12.4±2.1 Hepato-pancreato-biliary7 (8)20.2±1.9 Head and neck5 (5)15.8±1.8 Baseline characteristics of included patients Time toxicity details The median number of visits was 5 (range, 2–12). After a median of 65 days of follow-up, the mean time toxicity was 226 (95% CI 194 to 259) hours per patient, leading to a time toxicity index of 17% (95% CI 14% to 21%) of the follow-up time (table 2). The predominant components of time toxicity were travel time, with a mean of 6 (SD, 5) hours; time taken for hospital formalities, with a mean of 3 (SD, 0.98) hours; and infusion time, with a mean of 2 (SD, 2) hours (figure 4A). The median duration of a single outpatient visit was 11 (8–17) hours. A total of 97% of the outpatient visits were for chemotherapy; the rest were for routine check-ups or symptomatic care. The mean proportion of necessary to non-value-added activities was 8 (SD 9.4). Analysis of the trend of time toxicity over time revealed that time toxicity was initially high and then plateaued (figure 4B). Table 2Overall details of time toxicityVariablesSummaryRangeDistance from home to hospital59.5 (22.5,175.3)*5–395Number of hospital visits5 (4,7)*2–12Total time toxicity226.4 (156.4)†21.5–781.8Time toxicity index17.3 (15.7)†1.4–89Number of OP visits3.9 (2.2)†1–11Number of IP admissions2 (1,2)*0–7Total time toxicity of OP visits49.8 (35.1)†4–177.5 Travel time27.5 (24.3)†3–90 Time for hospital formalities15.4 (7.2)†1.3–32.4Infusion time10.4 (9)†1–89.2Time toxicity per OP visit10.9 (8.2, 17)*1–44.3 Travel time per hospital visit3.5 (1.5, 9.7)*0.4–17.5 Time for hospital formalities per hospital visit2.8 (2.3, 3.3)*0.6–5.8 Infusion time per hospital visit1.7 (1, 2.3)*0.2–12.7Total Time toxicity of IP admissions194.4 (165.1)†29–770.8*Summarised as median (Q1,Q3).†Summarised as mean(SD).IP, inpatient; OP, outpatient. Overall details of time toxicity Summarised as median (Q1,Q3). Summarised as mean(SD). IP, inpatient; OP, outpatient. (A) Components of time toxicity (B) Trend of time toxicity – from initial visits to the later visits of the patients. Of the 169 inpatient visits, 142 were for chemotherapy and 38 were for supportive care. The mean duration of hospital stay was 147 hours for those receiving chemotherapy and 70 hours for those receiving supportive care. The mean number of admissions was 2 (range 0–7). Only five patients had exclusively outpatient time toxicity. Among the 55 patients with inpatient and outpatient visits, 34 (62%) had hospital admissions only for chemotherapy. Seventeen (17/60, 28%) patients had one admission for supportive care, three patients had two admissions and one patient was admitted three times during the 2-month follow-up period. Survival and QoL of patients The median survival of the patient cohort was 8 months (95% CI 5.9 to not reached) after a median follow-up of 9 months (95% CI 8.4 to 9.5) (online supplemental Figure 2). The summary score of the EuroQoL at baseline was a median (IQR) value of 0.56 (0.38–0.69) and that at the end of the study was 0.43 (0.07–0.70). With treatment, QoL improved in 34 (37%) patients, and deterioration was noted in 58 (63%) patients. Correlation of time toxicity with other parameters Age, distance from the centre, education and QoL were assessed for correlations with time toxicity. Age and QoL were significantly associated with the time toxicity index (online supplemental table 1). With increasing age and QoL scores, there was a decrease in the average value of the time toxicity index on a logarithmic scale (online supplemental Figure 3). The time toxicity index on a log scale increased with the difference between QoL scores from baseline to the last follow-up. Discussion We report the first study from India exploring the time toxicity of palliative systemic therapy. The study revealed that patients with advanced malignancies with limited survival time spent 226 hours (9 days) during a 2-month period, corresponding to 17% of the follow-up time, on healthcare-related activities. The various components of time toxicity were travel and waiting times, with minor constituents of infusion times and doctor consults, with patients spending eight times more time on non-value-added activities than necessary activities, such as chemotherapy infusions. In patients with advanced malignancies, oncologists and patients need to consider the time toxicity associated with treatment options, especially if such therapies are only associated with marginal survival benefits. The results of the present study will help all stakeholders, including oncologists, palliative care physicians, patients and caregivers, to become aware of the novel concept of time toxicity and provide goal-concordant care for patients with advanced malignancies. Prior studies from high-income countries have eva luated the time costs of palliative treatment in different health systems. The most common method for the computation of time toxicity is to consider days of contact with healthcare systems as ‘toxic’ days, as proposed by Gupta et al.2 30 Similar to our study, the time toxicity was between one-third and one-fifth of the survival time reported in multiple studies of different solid tumours.6 9 31 Most other studies on time toxicity were retrospective analyses based on electronic medical records of deceased patients documenting patients’ contact with the healthcare system.6 However, our study was prospective and focused on a more comprehensive definition of time toxicity, as we wanted to understand all the determinants of time toxicity in our healthcare system. The time toxicity may depend on disease and treatment-related factors and the health system per se. A recent study that used a binary definition of time toxicity based on the frequency of contact with the healthcare system reported that 82% of patients with relapsed myeloma suffered time toxicity.32 The study again underlined the significant amount of time lost in medical care, irrespective of the definition of time toxicity. Although the median time toxicity index was 17%, some of our patients spent even 89% of the study period in the hospital. The median survival of our included patients was only 7 months, with almost 70% of the patients receiving the last line of therapy, indicating that the patient population selected was appropriate for the study. Since the inclusion time was not uniform for all our patients, the time toxicity trend over time plateaued after the first visit, whereas prior studies have demonstrated U-shaped curves, with increased contact days with healthcare near diagnosis and at the end of life.6 9 More time spent with doctors for explanations, more investigations and treatment initiation formalities may account for the longer visit durations (in hours) during the initial visits in our study. Our study revealed that better baseline QoL was associated with lower time toxicity, as those patients may have required fewer supportive care visits. Increased healthcare contact days were associated with worse survival and QoL in all patients receiving active treatment.33 Cancer care services are often concentrated in urban areas in India.34 The distance from home may accentuate the time toxicity due to the addition of long travel times. The time taken by patients for outpatient appointments is variable. Kagalwalla et al reported a median distance of 37 km and travel time of 50 min for outpatient visits by patients with cancer compared with 60 km and 3.5 hours (up to 17.5 hours) in our study.4 The total visit time in their study was 197 min, which was only one-third of the visit time in our study. In an Indian study, Seshachalam et al reported that one chemotherapy visit (excluding travel time) lasted approximately 6 hours, which is comparable to our findings.35 They reported the ratio of non-value-added time to total time of 41% vs 80% in our study. However, the non-value-added activities in our study included travel time, which was a major contributor to time toxicity. The implications of time toxicity may be different when considering curative intent treatment, which consists of chemotherapy visits predominantly vis-à-vis palliative intent treatment, with an increased need for supportive care.12 Time toxicity may be a function of multiple factors. The introduction of innovations in chemotherapy daycare centres, such as chemotherapy scheduling, reducing the laboratory turnaround time and changing the working of the chemotherapy unit, may help decrease the time spent on unnecessary activities.36,40 Based on each component of time toxicity, we suggest several measures to reduce the time costs of treatment for implementation in all centres catering to such patients (table 3). However, many obvious measures on paper are difficult to implement in the real world because of multiple issues. Table 3Interventions to decrease each component of time toxicity with the challenges in a low-income and middle-income country (LMIC)Components of time toxicity identifiedMitigation measuresIssues in LMICsPatient-related factorsTravel time Develop satellite centres, liaising with primary care physiciansTelemedicine consults for mid-cycle follow-upReferral to nearby cancer hospitals for chemotherapy cyclesArrange hospital transport options to transport all patients from the same area Inadequate access to trained physicians in the primary care centresInfrastructural limitations for the telemedicine unit, patient education for complying with instructionsAll cancer hospitals may not provide the same standards of care System-related factorsHospital formalities Card systems/kiosk systems to prevent queuing at the billing countersPharmacy preparednessLaboratory turnaround time to be reducedOutsource testing to local laboratories To educate patients regarding the use of swipe cardsPatient compliance with the appointment systemPossible only in bigger centres with sophisticated machinesThe standards of reporting at local laboratories are not uniform Waiting time for doctors Scheduling appointmentsIncrease trained supportive manpower for basic clinical care and patient counselling Compliance with the appointmentsPublic transport services may be convenient at particular times of the dayShortage of available trained personnel For consultations with other departments within and outside the cancer centre Form a multidisciplinary treatment team available in the same area so that the patients can seek all care in the same area Most of the LMIC cancer centres do not practise subspecialty-based oncology. In the general oncology setup, it may be difficult to bring all specialists to one place LMIC, Low- and Middle- income country . Interventions to decrease each component of time toxicity with the challenges in a low-income and middle-income country (LMIC) Develop satellite centres, liaising with primary care physicians Develop satellite centres, liaising with primary care physicians Telemedicine consults for mid-cycle follow-up Telemedicine consults for mid-cycle follow-up Referral to nearby cancer hospitals for chemotherapy cycles Referral to nearby cancer hospitals for chemotherapy cycles Arrange hospital transport options to transport all patients from the same area Arrange hospital transport options to transport all patients from the same area Inadequate access to trained physicians in the primary care centres Inadequate access to trained physicians in the primary care centres Infrastructural limitations for the telemedicine unit, patient education for complying with instructions Infrastructural limitations for the telemedicine unit, patient education for complying with instructions All cancer hospitals may not provide the same standards of care All cancer hospitals may not provide the same standards of care Card systems/kiosk systems to prevent queuing at the billing counters Card systems/kiosk systems to prevent queuing at the billing counters Pharmacy preparedness Pharmacy preparedness Laboratory turnaround time to be reduced Laboratory turnaround time to be reduced Outsource testing to local laboratories Outsource testing to local laboratories To educate patients regarding the use of swipe cards To educate patients regarding the use of swipe cards Patient compliance with the appointment system Patient compliance with the appointment system Possible only in bigger centres with sophisticated machines Possible only in bigger centres with sophisticated machines The standards of reporting at local laboratories are not uniform The standards of reporting at local laboratories are not uniform Scheduling appointments Scheduling appointments Increase trained supportive manpower for basic clinical care and patient counselling Increase trained supportive manpower for basic clinical care and patient counselling Compliance with the appointments Compliance with the appointments Public transport services may be convenient at particular times of the day Public transport services may be convenient at particular times of the day Shortage of available trained personnel Shortage of available trained personnel Form a multidisciplinary treatment team available in the same area so that the patients can seek all care in the same area Form a multidisciplinary treatment team available in the same area so that the patients can seek all care in the same area Most of the LMIC cancer centres do not practise subspecialty-based oncology. In the general oncology setup, it may be difficult to bring all specialists to one place Most of the LMIC cancer centres do not practise subspecialty-based oncology. In the general oncology setup, it may be difficult to bring all specialists to one place LMIC, Low- and Middle- income country . The current study only provides an idea regarding the average time spent by a patient with advanced malignancy in the hospital. The time spent in the hospital may have provided meaningful relief for patients and caregivers regarding having ‘done something’ to ‘treat’ cancer. In contrast, some patients may have perceived this as a ‘burden’ of hospital visits without benefits. Perspectives on time toxicity may depend on age, occupation, diagnosis, QoL and expected treatment benefits.7 Although oncologists tend to overestimate the importance of survival, a recent study reported that subsets of patients even chose treatment options without survival benefits for maintenance of QoL and lower toxicities.8 Oncologists may choose oral/subcutaneous treatment options to minimise supportive care visits. The metronomic treatment protocols commonly used in India are good examples of how oncologists try to reduce hospital visits for monitoring or supportive care.41,43 Qualitative studies have reported patients’ and caregivers’ perceptions of time toxicity, although not in India.44 45 Though the current study is the first Indian study to look at the time costs of therapy, it has several limitations. Ours was a single-centre study from a tertiary care academic cancer centre with a heterogeneous set of patients with advanced malignancies. However, the study may represent the overall time costs for patients with advanced malignancies. The patients’ oral reports were used to calculate the components of time toxicity; however, the total time toxicity was calculated more objectively. The time toxicity calculation included some essential activities like meals/en route breaks. However, the hours of time toxicity gave an idea regarding the elements of time toxicity in our healthcare system, thus opening avenues for interventions. Further studies are needed to calculate the time toxicity at multiple centres and health systems. However, until such studies are available, the findings of the current study may be applicable to other LMICs with similar healthcare systems. Oncologists can use the data from this study as a starting point for discussion regarding the time costs of treatment, thus helping patients decide between different treatment options. In the future, comparing two treatment modalities should also account for the difference in hospital time, as was demonstrated retrospectively in a study comparing two treatment options in older adults with acute myeloid leukaemia.26 46 There are efforts to increase pragmatic trials in oncology, with more inclusion of patient-reported outcomes or outcomes that matter.47 Conclusion The current study will help all stakeholders to understand the magnitude of the time spent on healthcare by patients with advanced malignancy in India and thus will serve to sensitise all the stakeholders to the important aspect of time toxicity (figure 5, Graphical abstract). Qualitative studies on the perspectives of patients, caregivers and oncologists on time toxicity are also needed to place the time toxicity in the correct context. Graphical abstract. Supplementary material Acknowledgements We gratefully acknowledge the Indian Society of Medical and Pediatric Oncology (ISMPO) for funding the study and the CReDO (The International Collaboration for Research Methods Development in Oncology) workshop for insights and guidance with protocol development. We thank Dr Manju Sengar, Dr Arjun Gupta, Dr Shankar Prinja and Dr Gaurav Jyani for their timely help and suggestions in the paper. We also acknowledge all the patients who participated in the study and cooperated wholeheartedly in the data collection process. We also thank Mrs Mangaiyarkarasi S and Mrs Prathika Sherigar for their help in the paperwork associated with the protocol development. Footnotes Funding: The Indian Society of Medical and Pediatric Oncology (ISMPO/2023-24/002) funded the study for the provision of manpower for data collection. Provenance and peer review: Not commissioned; internally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants and was conducted after approval (346/2022) by the Kasturba Medical College and Kasturba Hospital Institutional Ethics Committee and registration in the clinical trials registry (CTRI/2023/05/053281). The patients were included only after providing written informed consent. Overall, the study procedures followed the ethical principles laid down by the Indian Good Clinical Practice Guidelines (ICMR 2017). The methodology and results were reported as per the Strengthening the Reporting of Observational Studies in Epidemiology checklist to ensure comprehensive and transparent reporting. Participants gave informed consent to participate in the study before taking part. Data availability free text: Anonymised data underlying this article will be shared on reasonable request to the first author. Data availability statement Data are available on reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available on reasonable request.